Tirza
Generic Name
Tirza
Manufacturer
MediCorp Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tirza 5 mg injection | ৳ 2,800.00 | N/A |
Description
Overview of the medicine
Tirza 5 mg Injection is a novel anti-diabetic medication that acts as a dual GIP and GLP-1 receptor agonist, primarily indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. It may also be used for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
Uses & Indications
Dosage
Adults
Initial dose 2.5 mg subcutaneously once weekly for 4 weeks. Then, increase to 5 mg once weekly. Further dose escalations (in 2.5 mg increments) may be made every 4 weeks based on glycemic control and tolerability, up to a maximum of 15 mg once weekly.
Elderly
No dose adjustment is required based on age. However, monitor renal function in elderly patients, as they may have decreased renal clearance.
Renal_impairment
No dose adjustment is recommended for patients with mild, moderate, or severe renal impairment, or end-stage renal disease. Exercise caution and monitor for adverse effects.
How to Take
Administer Tirza subcutaneously once weekly, any time of day, with or without meals. Inject into the abdomen, thigh, or upper arm. Rotate injection sites. Do not mix Tirza with insulin or other injectables in the same syringe.
Mechanism of Action
Tirza functions as an agonist for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual action enhances glucose-dependent insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces food intake through central effects, collectively leading to improved glycemic control and weight reduction.
Pharmacokinetics
Onset
Clinical effects on glucose control are observed within days to weeks of initiation.
Excretion
Excreted via urine and feces as metabolites.
Half life
Approximately 5 days (120 hours), allowing for once-weekly dosing.
Absorption
Slow absorption after subcutaneous injection, with peak plasma concentrations typically reached 24-48 hours post-dose.
Metabolism
Primarily metabolized by proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid moiety.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to Tirza or any of its excipients
- Pregnant or breastfeeding women
Drug Interactions
Oral contraceptives
May reduce the efficacy of oral contraceptives due to delayed gastric emptying. Advise patients using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and each dose escalation of Tirza.
Drugs with a narrow therapeutic index
Monitor closely, as Tirza may delay gastric emptying and affect their absorption.
Insulin secretagogues (sulfonylureas) or Insulin
Increased risk of hypoglycemia. Dose reduction of insulin or sulfonylureas may be required.
Storage
Store Tirza in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If necessary, Tirza can be kept unrefrigerated for a maximum of 21 days at a temperature not exceeding 30°C (86°F). Protect from light.
Overdose
In the event of an overdose, adverse gastrointestinal effects (e.g., severe nausea, vomiting) and hypoglycemia may occur. Supportive treatment appropriate to the patient’s clinical signs and symptoms should be initiated. Due to the long half-life, prolonged observation may be necessary.
Pregnancy & Lactation
Tirza is not recommended during pregnancy due to potential fetal harm observed in animal studies. Use only if the potential benefit justifies the potential risk to the fetus. It is unknown if Tirza is excreted in human milk; caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to Tirza or any of its excipients
- Pregnant or breastfeeding women
Drug Interactions
Oral contraceptives
May reduce the efficacy of oral contraceptives due to delayed gastric emptying. Advise patients using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and each dose escalation of Tirza.
Drugs with a narrow therapeutic index
Monitor closely, as Tirza may delay gastric emptying and affect their absorption.
Insulin secretagogues (sulfonylureas) or Insulin
Increased risk of hypoglycemia. Dose reduction of insulin or sulfonylureas may be required.
Storage
Store Tirza in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If necessary, Tirza can be kept unrefrigerated for a maximum of 21 days at a temperature not exceeding 30°C (86°F). Protect from light.
Overdose
In the event of an overdose, adverse gastrointestinal effects (e.g., severe nausea, vomiting) and hypoglycemia may occur. Supportive treatment appropriate to the patient’s clinical signs and symptoms should be initiated. Due to the long half-life, prolonged observation may be necessary.
Pregnancy & Lactation
Tirza is not recommended during pregnancy due to potential fetal harm observed in animal studies. Use only if the potential benefit justifies the potential risk to the fetus. It is unknown if Tirza is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture when stored as recommended.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by regulatory bodies (e.g., FDA, DGDA)
Patent Status
Patented
Clinical Trials
Extensive phase 3 clinical trial programs (e.g., SURPASS and SURMOUNT programs for Tirzepatide) have demonstrated superior efficacy of Tirza in glycemic control and weight reduction compared to other anti-diabetic medications and placebo.
Lab Monitoring
- HbA1c levels (regularly)
- Blood glucose levels (fasting and postprandial)
- Renal function (creatinine, eGFR) periodically
- Pancreatic enzymes (amylase, lipase) if pancreatitis is suspected
Doctor Notes
- Educate patients thoroughly on proper injection technique and the importance of injection site rotation to minimize adverse reactions.
- Closely monitor patients for signs and symptoms of pancreatitis and gallbladder disease.
- Adjust concomitant insulin or sulfonylurea doses to mitigate the risk of hypoglycemia.
Patient Guidelines
- Always use Tirza as directed by your doctor.
- Do not share your Tirza injection pen with others, even if the needle is changed, to prevent infection.
- Store Tirza in the refrigerator and protect it from light. Do not freeze.
Missed Dose Advice
If a dose is missed, administer it as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose and resume the regular once-weekly schedule. Do not take two doses within 48 hours.
Driving Precautions
Tirza has no or negligible influence on the ability to drive and use machines. However, patients should be advised to take precautions to avoid hypoglycemia, especially when Tirza is used in combination with insulin or sulfonylureas, which can impair concentration and reaction time.
Lifestyle Advice
- Tirza works best when combined with a balanced diet and regular exercise routine. Consult your doctor or a nutritionist for a personalized plan.
- Monitor your blood sugar levels regularly as advised by your doctor to ensure effective management and detect hypoglycemia early.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Tirza Brand
Other medicines available under the same brand name
